EGFR and non-small cell lung carcinoma: A randomized trial of osimertinib with or without SRS for EGFR-mutated NSCLC with BMs from the Trans-Tasman Radiation Oncology Group to compare the iPFS at 12 months is ongoing (NCT03497767).